Background: Preterm labor and miscarriage may occur in stressful situations, such as a surgical operation or infection during pregnancy. Pharyngeal and buccal abscess and facial bone fractures are inevitable dental surgeries in pregnant patients. Remifentanil is an opioid analgesic that is commonly used for general anesthesia and sedation. Nonetheless, no study has investigated the effects of remifentanil on amniotic epithelial cells. This study evaluated the effects of remifentanil on the factors related to uterine contraction and its mechanism of action on amniotic epithelial cells. Methods: Amniotic epithelial cells were preconditioned at various concentrations of remifentanil for 1 h, followed by 24-h lipopolysaccharide (LPS) exposure. MTT assays were performed to assess the cell viability in each group. The effects of remifentanil on factors related to uterine contractions in amniotic epithelial cells were assessed using a nitric oxide (NO) assay, western blot examinations of the expression of nuclear factor-kappa B (NF-κB), cyclooxygenase 2 (COX2), and prostaglandin E2 (PGE2), and RT-PCR examinations of the expression of the proinflammatory cytokines interleukin (IL)-1β and tumor necrosis factor-alpha (TNF-α). Results: Remifentanil did not affect viability and nitric oxide production of amniotic epithelial cells. Western blot analysis revealed that remifentanil preconditioning resulted in decreased expressions of NF-κB and PGE2 in the cells in LPS-induced inflammation, and a tendency of decreased COX2 expression. The results were statistically significant only at high concentration. RT-PCR revealed reduced expressions of IL-1β and TNF-α. Conclusions: Preconditioning with remifentanil does not affect the viability of amniotic epithelial cells but reduces the expression of factors related to uterine contractions in situations where cell inflammation is induced by LPS, which is an important inducer of preterm labor. These findings provide evidence that remifentanil may inhibit preterm labor in clinical settings.
INTRODUCTION
Preterm birth accounts for approximately 10% of all pregnancies and is the main cause of neonatal death.
The death rate of preterm infants from preterm birth is approximately 70% [1] . Although a number of drugs are currently used to prevent preterm births, rates of preterm labor and miscarriage are still high and have been continuously increasing, especially with the increasing number of pregnancies at advanced maternal ages [2] .
Thus, elucidating the complex pathophysiology of preterm labor and miscarriage, and identifying effective drugs are very important.
Pregnancy and delivery are regulated by several close connections between hormones and cytokines. A large number of factors that are important for regulating pregnancy and delivery are produced in pregnancy-related tissues, including the placenta and amnion. An imbalance among these factors may cause preterm labor and birth, which could be fatal to both the mother and fetus [3] .
Preterm labor and miscarriage may occur in stressful situations, such as a surgical operation or infection during pregnancy [4] . In the dental clinic, pharyngeal and buccal abscesses and facial bone fractures are inevitable surgeries in pregnant patients. Drugs used for surgeries other than obstetric surgeries during pregnancy must relax the mother's uterus as much as possible to prevent preterm birth, while anesthetics used for cesarean section or drugs used for pain relief during delivery must have a minimal impact on the myometrium of the mother as well as a minimal negative effect on the fetus.
Delivery due to preterm labor eliminates the opportunity for the maturation that can be necessary for survival of the fetus. Problems that include low birth weight and premature development of the lungs occur more frequently and the survival rate decreases with the gestational age at delivery [5] . Thus, studies have continued to evaluate drugs that effectively reduce uterine contraction and have a minimal effect on the safety of the mother and fetus.
Remifentanil is an ultra-short-acting μ-opioid receptor agonist characterized by fast onset of action and degradation [6] . Although remifentanil is an opioid analgesic that is commonly used for general anesthesia and sedation in oral and maxillofacial surgery, no study has investigated the effects of remifentanil on amniotic epithelial cells, which produce the factors required for the regulation of pregnancy and delivery. This study investigated the effects of remifentanil on the factors related to uterine contraction and its mechanism of action on amniotic epithelial cells. 
MATERIALS AND METHODS

Remifentanil treatment
Commercially available remifentanil was used (GlaxoSmithKline, Brentford, UK). It was diluted in culture medium and added to cell cultures at concentrations ranging from 0.001-1 μg/ml for 1 h. The cells were then treated with growth medium only or with medium containing lipopolysaccharide (LPS; 1 μg/ml) for 24 h. PCR-amplified products were separated on a 1.5% stained agarose gels. The Gel Doc ImageQuant LAS 500 System (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was used to assay the PCR products. β-actin was used to normalize all target genes. The data were analyzed using the Image J program.
Statistical analyses
Data are expressed as means ± standard deviation of 
RESULTS
Effects of remifentanil treatment on cell viability and proliferation
The viability of amniotic epithelial cells was not affected by the different concentrations of remifentanil (Fig. 1 ).
Effects of remifentanil treatment on NO concentrations
There was no difference in NO concentration in the remifentanil preconditioned group compared to the control group. NO production in amniotic epithelial cells was not affected by remifentanil (Fig. 2 ).
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Effects of remifentanil treatment on the NF-κ B pathway
Western blot analysis revealed that preconditioning with remifentanil reduced NF-κB expression after inducing inflammation in cells using LPS (Fig. 3) .
Effects of remifentanil treatment on proinflammatory cytokines (IL-1β , TNF-α )
RT-PCR analysis showed that preconditioning with remifentanil reduced IL-1β and TNF-α expression after inducing inflammation in cells using with LPS (Fig. 4) .
Effects of remifentanil treatment on COX2 and PGE 2
Western blot analysis showed that preconditioning with remifentanil reduced PGE 2 expression after LPS induction of cell inflammation. However, COX2 expression was decrease. The decrease was not statistically significant at low concentrations of remifentanil but was statistically significant at the highest concentration of remifentanil (Fig. 5) .
DISCUSSION
The purpose of this study was to determine the effects of remifentanil on the factors related to uterine contractions in amniotic epithelial cells. There are several key findings. First, remifentanil did not affect the viability and NO production of amniotic epithelial cells. Remifentanil can thus be considered as a safe drug with no effect on cell survival rate. NO, which is increased during pregnancy, is an important regulator of uterine contraction [7] . Remifentanil appears to have no effect on NO-mediated uterine relaxation.
Second, preconditioning with remifentanil reduced NF-κ Fig. 4 . RT-PCR analysis showed that preconditioning with remifentanil reduced IL-1β and TNF-α expression after inducing inflammation in cells using lipopolysaccharide (LPS). ## P < 0.01, ### P < 0.001 versus control group; *P < 0.05, **P < 0.01, ***P < 0.001 versus LPS group.
B expression in the LPS-induced inflammatory condition. NF-κB is a transcription factor that is an important regulator of factors involved in the immune response, including cytokines, inducible NO synthase, COX2, and adhesion molecules. Several reports have established the regulation of NF-κB to bear the potential to control various inflammatory diseases [8] [9] [10] . Based on the previous and present findings, we speculate that remifentanil inhibits NF-κB signaling pathways.
Lastly, preconditioning with remifentanil reduced the expression of the inflammatory cytokines IL-1β and TNF-α, and PGE2 in the LPS-induced inflammatory condition.
Expression of COX2 showed a decreasing tendency at low concentrations that was not statistically significant;
however, a statistically significant decrease was observed at the highest concentration.
Endotoxins like LPS stimulate an inflammatory response and cause the production of proinflammatory cytokines, including TNF-α and IL-6, which induces a hyperinflammatory state [11] . The severity of the systemic inflammatory response strongly correlates with the plasma levels of proinflammatory cytokines [12] . Presently, the levels of the IL-1β and TNF-α proinflammatory cytokines were significantly reduced in cells preconditioned with Preconditioning with remifentanil reduced PGE2 expression after inducing inflammation in cells using lipopolysaccharide (LPS). The expression of COX2 tended to decrease non-significantly at low concentrations and was statistically significant at the highest concentration of remifentanil (1 μg).
## P < 0.01, ### P < 0.001 versus control group; *P < 0.05, **P < 0.01, ***P < 0.001 versus LPS group.
remifentanil before LPS exposure, compared with cells treated solely with LPS.
PGE2 plays an important role in labor, including cervical ripening and contraction of the uterus. It can, however, lead to excessive uterine contraction [13] .
Although the results of this study indicate that COX2 expression is not affected by remifentanil, the finding that PGE 2 expression was reduced with remifentanil preconditioning indicates that remifentanil may reduce uterine contraction. Several studies have investigated the effects of drugs used for general anesthesia on the myometrium using animal myometrium tissue slices [14] [15] [16] . Nacitarhan et al. [15] reported that remifentanil reduces myometrial contraction in the uterine muscle of pregnant rats. Although COX2 is rarely expressed in normal conditions, it is rapidly induced by stimulation of molecules like LPS. This plays a critical role in the inflammatory response [17] . These results suggest that the reduction of COX2 expression at high concentrations of remifentanil cannot completely rule out the effect of remifentanil on COX2 expression.
Remifentanil is an ultra-short-acting μ-opioid receptor agonist. It is metabolized by hydrolysis of its ester linkage by a nonspecific plasma and tissue esterase. Remifentanil is widely used owing to the fast onset and dissolution of action [6] . Although its anti-inflammatory effect has been reported previously, no study has examined the its effects on amniotic epithelial cells [18, 19] . 
